Tarsus Pharmaceuticals is broadening its ophthalmology portfolio by purchasing Alkeus Pharmaceuticals, its second acquisition in as many months.
To broaden its ophthalmology portfolio, Tarsus Pharmaceuticals is dishing out $450 million upfront to acquire Phase 3 biotech Alkeus Pharmaceuticals, the companies
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger…
Astellas Pharma is aiming to double sales for its five key medicines, including Pfizer-partnered bladder cancer drug Padcev,…
Ipsen's Dysport meets Phase 3 endpoints in migraine, Tarsus acquires iRenix for $75M+, Alchemab raises $34M, and more.
Korean biotechnology firm Alteogen said Wednesday it has signed an exclusive licensing agreement worth up to $365 million with a…
Pfizer CFO exits; GSK wins FDA nod for oral UTI drug; Apellis trial paused; plus Mersana ADC dropped, TORL ADC data, Corcept…
Cartesian’s $150M financing; Editas Medicine’s money moves
